BGA
SGYP

Belmont Global Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Belmont Global Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.1M Buy
+200,000
New +$936K 1.04% 19
2014
Q3 		– Sell
-7,000
Closed -$28K – 144
2014
Q2 		$28K Buy
+7,000
New +$29.7K 0.02% 129

Other funds holding SGYP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Belmont Global Advisors's SGYP Position: Q3 2016 in Review

Belmont Global Advisors reduced its Synergy Pharmaceuticals, Inc Common Stock (SGYP) stake by 30% in Q3 2016, selling an estimated $538K and leaving 270,000 shares worth $1.49M. The position accounts for 1.41% of the portfolio, ranked #11.

Belmont Global Advisors first reported a position in SGYP in Q4 2013 and has held it in 11 quarters since. 149 funds tracked by Wall St. Rank hold SGYP as of Q3 2016.

  • Belmont Global Advisors held 270,000 shares of Synergy Pharmaceuticals, Inc Common Stock worth $1.49M as of Q3 2016.
  • Belmont Global Advisors sold 115,000 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2016, an estimated $538K.
  • Synergy Pharmaceuticals, Inc Common Stock made up 1.41% of Belmont Global Advisors's portfolio in Q3 2016, its #11 holding.
  • Belmont Global Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2013 and has held it in 11 quarters since.
  • 149 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2016.

Based on Belmont Global Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.